# Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

> **NCT05188664** · PHASE1,PHASE2 · COMPLETED · sponsor: **LaNova Australia Pty Limited** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-302
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05188664
- **Lead sponsor:** LaNova Australia Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-10
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188664, "Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05188664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*